Writing on the IPKat weblog -- a general interest intellectual property blog which many readers of this blog do not get to read -- England-based Australian lawyer Catherine Lee has posted
this summary of "Should Patents on Pharmaceuticals Be Extended to Encourage Innovation?", a
Wall Street Journal feature in the form of a debate between Josh Bloom (director of Chemical and Pharmaceutical Sciences at the American Council on Science) and Els Torreele (director of the Access to Essential Medicines Initiative of the Open Society Foundation's Public Health Program) as to whether pharma patents should be incentivised by longer patents or funded through the infusion of funds within a regulatory environment.
Readers who wish to give Catherine the benefit of their opinion are invited to do so.
No comments:
Post a Comment